CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 65 enrolled
Drug / intervention
huCART-meso cellsbiological
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Histologically confirmed metastatic/recurrent lung adenocarcinoma, persistent/recurrent serous epithelial ovarian cancer, primary peritoneal carcinoma, fallopian tube carcinoma, or malignant pleural/peritoneal mesothelioma (epithelial type)
  • ✓Failure of at least one prior standard of care chemotherapy for advanced stage disease
  • ✓Measurable disease by RECIST 1.1 or modified RECIST (mesothelioma)
  • ✓Age ≥18 years
Key exclusion· 12
  • ✕Sarcomatoid or biphasic mesothelioma
  • ✕Known leptomeningeal carcinomatosis or spinal cord compression
  • ✕Symptomatic CNS metastases
  • ✕Active invasive cancer other than study cancers (non-invasive cancers allowed)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03054298
NCT03054298Phase 1Completed
CompareCT.gov

Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers

University of Pennsylvania·interventional·Posted Feb 15, 2017·Updated Apr 29, 2025

In Brief

A Phase 1 clinical trial evaluating huCART-meso cells for Lung Adenocarcinoma and 5 related conditions. Completed, enrolled 65 participants across 1 site.

Detailed Summary

Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer, Mesotheliomas Pleural, Mesothelioma Peritoneum
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Tmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company)

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 15, 2017
Enrollment StartApr 6, 2017
Primary CompletionNov 9, 2023
Study CompletionJul 30, 2024
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 9.4 years ago

Interventions

huCART-meso cellsbiological

Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..